Iron toxicity: relevance for dialysis patients.
Study Goal
The researchers aimed to review issues related to iron toxicity and assess the safety and efficacy of intravenous iron in hemodialysis patients.
Results Summary
The study found that intravenous iron effectively raises hemoglobin levels and reduces erythropoiesis-stimulating agent dose requirements, but its safety regarding patient-centered outcomes remains inadequately studied. Potential safety concerns were noted, but most studies had small sample sizes and unclear clinical relevance.
Population
Hemodialysis patients with advanced kidney disease
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Intravenous iron | increase | hemoglobin levels | hemodialysis patients | - | rise | #1 |
Intravenous iron | decrease | erythropoiesis-stimulating agent dose requirements | hemodialysis patients | - | reduced | #2 |
Iron deficiency is common among patients with advanced kidney disease, particularly those requiring hemodialysis. Intravenous iron is a convenient treatment to supplement iron and is widely used among hemodialysis patients. Its efficacy is well established that, with treatment, hemoglobin levels rise and erythropoiesis-stimulating agent dose requirements are reduced. However, the safety of intravenous iron with respect to patient-centered outcomes has not been adequately studied. A variety of studies have indicated potential safety concerns, but most have been of small numbers of patients and with end points studied that have unclear clinical relevance. In this study, issues related to iron toxicity are reviewed.